Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs)
- Triple reuptake inhibitors: one molecule blocks SERT, NET and DAT
- Cocaine is the archetype; centanafadine is the therapeutic candidate, developed for ADHD
- Dopamine reuptake blockade brings stimulant-like benefit and the abuse liability that tracks how fast DAT occupancy rises
- The serotonin component counts toward serotonin toxicity with an MAOI
Class at a glance
- Triple reuptake inhibitors: one molecule blocks SERT, NET and DAT
- Cocaine is the archetype; centanafadine is the therapeutic candidate, developed for ADHD
Clinical role
- Dopamine reuptake blockade brings stimulant-like benefit and the abuse liability that tracks how fast DAT occupancy rises
- The serotonin component counts toward serotonin toxicity with an MAOI
Self-check
- What separates an SNDRI from an SNRI?
Dopamine transporter blockade — the third transporter, and the one that carries the stimulant effect and misuse liability.
Drugs in this class (2)
All drug classes · Open Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs) in the interactive console ↗